Anti-LFA-1 therapy induces long-term islet allograft acceptance in the absence of IFN-gamma or IL-4.
mAb therapy directed against a variety of cell surface accessory molecules has been effectively utilized to prolong allograft acceptance in various models of tissue and organ transplantation. The purpose of this study was to determine whether transient therapy directed against the adhesion molecule LFA-1 (CD11a) was sufficient to induce donor-specific tolerance to pancreatic islet allografts. Anti-LFA-1 monotherapy was found to be efficacious in inducing long-term islet allograft acceptance in multiple donor-recipient strain combinations. Graft acceptance following anti-LFA-1 therapy was not simply due to clonal ignorance of donor Ags in that the majority of recipients bearing established islet allografts resisted rejection induced by immunization with donor-type APCs. Furthermore, donor-specific tolerance from anti-LFA-1-treated animals could be transferred to secondary immune-deficient animals. Taken together, these results indicated that transient anti-LFA-1 monotherapy resulted in donor-specific tolerance. In vitro, functionally tolerant animals retained normal anti-donor reactivity as assessed by proliferative, cytotoxic, and cytokine release assays that demonstrated that tolerance was not secondary to general clonal deletion or anergy of donor-reactive T cells. Finally, anti-LFA-1 treatment was effective in both IL-4-deficient and IFN-gamma-deficient recipients, indicating that neither of these cytokines are universally required for allograft acceptance. These results suggest that anti-adhesion-based therapy can induce a nondeletional form of tolerance that is not overtly dependent on the prototypic Th1 and Th2 cytokines, IFN-gamma and IL-4, respectively, in contrast to results in other transplantation models.
Nicolls
M R
MR
Division of Pulmonary Sciences, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences University, Denver, CO 80262, USA.
Coulombe
M
M
Yang
H
H
Bolwerk
A
A
Gill
R G
RG
D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017635:Clonal Anergy / Q000235:genetics; D017637:Clonal Deletion / Q000235:genetics; D002999:Clone Cells; D003433:Crosses, Genetic; D006085:Graft Survival / Q000235:genetics / Q000276:immunology*; D007108:Immune Tolerance / Q000235:genetics; D007371:Interferon-gamma / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D015847:Interleukin-4 / Q000172:deficiency* / Q000235:genetics* / Q000502:physiology; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D018345:Mice, Knockout; D016513:Mice, SCID; D013045:Species Specificity; D013154:Spleen / Q000166:cytology / Q000637:transplantation; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D016169:Lymphocyte Function-Associated Antigen-1; D015847:Interleukin-4; D007371:Interferon-gamma